Company Description
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients.
The company also develops RAD 302, an αvβ6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors.
It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.
The company was incorporated in 2021 and is based in Carlton, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Riccardo Canevari |
Contact Details
Address: 62 Lygon Street, Level 3 Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | radiopharmtheranostics.com |
Stock Details
| Ticker Symbol | RADX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001949257 |
| ISIN Number | US75041J1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riccardo Canevari | MD, Chief Executive Officer and Director |
| Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder and Executive Chairman |
| Phillip Hains | Chief Financial Officer, Joint Company Secretary and Director |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Nathan Jong C.A. | Joint Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 28, 2025 | 6-K | Report of foreign issuer |
| Jul 23, 2025 | SCHEDULE 13G | Filing |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| Jul 16, 2025 | 6-K | Report of foreign issuer |
| Jun 24, 2025 | 6-K | Report of foreign issuer |
| Jun 12, 2025 | 6-K | Report of foreign issuer |
| Jun 11, 2025 | 6-K | Report of foreign issuer |
| Jun 4, 2025 | 6-K | Report of foreign issuer |